# TB-500 FAQ: Questions from the Research Community, Answered from the Literature > TB-500 frequently asked questions — what it is, how it works, dosage context, side effects, comparison with BPC-157, WADA status, and the limits of the current evidence base. Cited from published studies. Twenty-five questions drawn from keyword research and community discussion, answered directly from the peer-reviewed literature and the limits of what it shows. ## Definitions and Basics ### What is TB-500? TB-500 is a synthetic heptapeptide (Ac-LKKTETQ) corresponding to amino acids 17–23 of Thymosin Beta-4, an endogenous signaling protein studied for its role in actin regulation, cell migration, and tissue repair in preclinical models. The acetylated N-terminus distinguishes it from the native TB4 sequence. Molecular weight: 887 daltons. ### What does TB-500 stand for? TB-500 refers to Thymosin Beta-500 — a naming convention used in research and anti-doping contexts for the synthetic heptapeptide fragment corresponding to residues 17–23 of Thymosin Beta-4. The '500' designation appeared in early peptide synthesis literature to distinguish the fragment from the parent protein. In current research it is more precisely labeled Ac-LKKTETQ or N-acetyl-LKKTETQ. ### What is the relationship between TB-500 and Thymosin Beta-4? Thymosin Beta-4 (Tβ4) is the full endogenous 43-amino-acid protein. TB-500 is a synthetic 7-amino-acid fragment corresponding to its actin-binding region (residues 17–23). TB-500 preserves the G-actin sequestration activity of Tβ4 but may not replicate all of the parent protein's biological effects. The full protein has been studied in human clinical trials; the fragment has not. The two are mechanistically related but not pharmacokinetically equivalent. ### Is TB-500 a steroid? No. TB-500 is a synthetic peptide — a short amino acid chain. It is structurally and mechanistically distinct from anabolic steroids, which are lipid-soluble cholesterol derivatives acting on nuclear receptors. TB-500 acts on G-actin cytoskeletal dynamics and VEGFR2-mediated cell-surface signaling. WADA classifies it under S2 (Peptide Hormones, Growth Factors, Related Substances) — the peptide category. ### What peptides does TB-500 combine with in research stacks? TB-500 is most commonly co-discussed with BPC-157 in what researchers and community literature label the 'Wolverine stack' — hypothesized to combine BPC-157's GI-protective and tendon-fibroblast-specific effects with TB-500's systemic angiogenic and anti-fibrotic properties. No published peer-reviewed study has tested the two together in a controlled design. All combination claims derive from extrapolation from each compound's independent preclinical literature. ## Mechanism and Effects ### How does TB-500 work? TB-500 binds monomeric G-actin in a 1:1 stoichiometric ratio, sequestering it and modulating cytoskeletal dynamics. This promotes cell motility and migration, upregulates VEGFR2-mediated angiogenesis, reduces inflammation via microRNA-146a upregulation and macrophage M2 polarization, and activates ILK/Akt survival signaling in cardiomyocytes. Multiple downstream effects emerge from that single actin-binding interaction. ### What is TB-500 used for in research? Preclinical research has examined TB-500 and Thymosin Beta-4 in models of wound closure [1, 2], tendon and ligament repair [3], cardiac tissue regeneration post-infarction [4, 5], hair follicle stem cell activation [6], traumatic brain injury [8], axon regeneration [19], and liver inflammation and fibrosis [14, 21]. No FDA-approved human indication exists for the compound. ### What is the benefit of BPC-157 and TB-500 together? Researchers have studied BPC-157 and TB-500 as mechanistically complementary: BPC-157 is associated with GI protection, tendon fibroblast activity, and local angiogenesis; TB-500 is studied for systemic actin-cytoskeletal modulation, VEGFR2-mediated angiogenesis, and anti-fibrotic effects. The hypothesized complementarity is mechanistically plausible based on each compound's independent preclinical record. Combined protocols appear in anecdotal literature; head-to-head human trials are absent. ### Does TB-500 increase hair growth? Thymosin Beta-4 activated quiescent hair follicle stem cells in the bulge region at nanomolar concentrations in rodent vibrissal follicle models, stimulating keratinocyte migration, differentiation, and MMP-2 secretion [6]. TB-500 (the synthetic 7-residue fragment) has not been independently validated for hair growth in peer-reviewed trials. The hair follicle findings come from full-length Tβ4 studies. ### Is TB-500 good for the heart? Thymosin Beta-4 has been studied in murine myocardial infarction models, where ILK/Akt pathway activation promoted cardiomyocyte survival [4] and AAV-delivered Tβ4 reduced cardiac inflammation and fibrosis via mitophagy promotion [5]. These are preclinical findings in mice. No human cardiac efficacy trial for Tβ4 or TB-500 has been published in peer-reviewed literature. ### Does TB-500 help the heart? Preclinical cardiac models (primarily murine) show Thymosin Beta-4 promotes angiogenesis and reduces cardiomyocyte apoptosis post-injury via ILK/Akt signaling. Two independent murine MI studies confirmed cardiac protective effects [4, 5]. Human cardiac efficacy evidence is absent from the published literature. ### Does TB-500 only work for physical injury or can it help with systemic inflammation? The research literature extends beyond musculoskeletal injury. Tβ4 has been studied for anti-inflammatory effects in cardiac tissue [5], liver fibrosis [14], NAFLD [21], and traumatic brain injury [8]. The mechanism — macrophage M2 polarization, MAPK/NF-κB pathway suppression, miR-146a upregulation — is systemic rather than tissue-specific. Whether the 7-residue TB-500 fragment reproduces systemic anti-inflammatory effects observed with the full Tβ4 protein has not been validated in published studies. ## Dosage and Administration ### How much TB-500 should I take? This reading room describes research quantities used in published animal studies — not clinical recommendations. Preclinical animal studies use weight-based dosing ranging from 1 µg local (rat ligament) [3] to 12 mg/kg/day IP (mouse liver model) [21]. Extrapolation to humans is not validated. This is research context only. ### Can TB-500 be taken every day? Preclinical protocols vary. Some animal studies use daily administration (the NAFLD model at 12 mg/kg/day [21]); others use 2–3× weekly (Spurney et al. 2010, twice weekly × 6 months in mdx mice [16]). The human Phase I IV trial used daily dosing over 14 days for the repeat-dose cohort [9]. No validated human dosing schedule exists for musculoskeletal or systemic indications. ### How quickly does TB-500 work? Animal studies report measurable tissue-repair markers within days to weeks, depending on the model: wound re-epithelialization improvements were measured at day 4 and day 7 [2]; ligament histological improvements at 4 weeks [3]; neurological TBI improvements at 35 days [8]. No validated human onset data is available. ### How long does TB-500 stay in your system? No peer-reviewed human pharmacokinetic data for TB-500 (Ac-LKKTETQ) specifically. For full-length Tβ4, human Phase I IV data confirmed dose-proportional pharmacokinetics with no accumulation on 14-day repeat dosing [9, 10]. Specific half-life values were not published in available abstracts. Detection windows in anti-doping contexts have been partially characterized in equine samples by LC-MS/MS [12], but human detection window data has not been published in peer-reviewed form. ### Can TB-500 be taken orally? Most preclinical research administers TB-500/Tβ4 via subcutaneous, intraperitoneal, local/intralesional, or intravenous routes. Oral peptide delivery faces proteolytic degradation in the GI tract. Oral bioavailability of TB-500 has not been established in peer-reviewed studies in any species. Community-context oral administration anecdotes exist but are not supported by published pharmacokinetic evidence. ### Where to inject TB-500? Animal studies employ subcutaneous and intramuscular injection routes in rodent models. Intravenous and intraperitoneal routes appear in some rodent and human Phase I protocols. The anti-doping equine literature identifies subcutaneous as the route for which detection methodology was validated [12]. Injection-site preference in community research contexts is anecdotal and not addressed in the clinical literature. ### How to reconstitute TB-500? Research laboratory preparations of Tβ4 and TB-500 for animal studies use bacteriostatic water or sterile saline as the diluent for injectable preparations. Stability and concentration vary by study protocol; no standardized clinical reconstitution guideline exists. This reflects research practice, not a preparation instruction. ### Do you NEED to keep dosing TB-500 to maintain results? The published literature does not address maintenance dosing in the context of this question. The chronic mdx mouse study (Spurney 2010) administered twice-weekly IP for 6 months and showed increased regenerating fiber count; no follow-up data characterized what happened post-cessation [16]. For wound healing studies, treatment periods were short-course and endpoint measurement was at defined time points. Maintenance dosing claims in community contexts are not derived from controlled clinical evidence. ## Safety and Regulatory ### What are the side effects of TB-500? In animal studies, TB-500 and Tβ4 are generally well-tolerated. Human Phase I trials of full-length Tβ4 reported infrequent, mild-to-moderate adverse events with no dose-limiting toxicities at IV doses up to 1260 mg in 40 volunteers [9, 10]. Anecdotal adverse events in human community contexts include injection-site reactions, temporary fatigue, and mild dizziness. Long-term human safety data for the synthetic TB-500 fragment does not exist in peer-reviewed form. ### What are the side effects of TB-500 combined with BPC-157? No formal human safety studies exist for the TB-500 + BPC-157 combination, and no controlled animal study of the combination has been published in indexed literature. Anecdotal reports cite similar individual adverse events — injection-site reactions and fatigue — without documented additive toxicity in the available literature. The combination data gap is real. ### What are the bad side effects of taking peptides? Research peptides carry risks including injection-site reactions, immune responses to exogenous protein sequences, unknown long-term effects, and purity concerns from unregulated commercial sources. TB-500 has not been approved by the FDA for human use. Any injectable compound used outside a controlled medical setting carries inherent infection risk from non-sterile technique. ### Who should avoid peptides? Clinical commentary notes that individuals with active malignancy, autoimmune conditions, or during pregnancy warrant particular caution — Tβ4's pro-angiogenic and cell-migration-promoting mechanisms are theoretically relevant in contexts where those processes are already dysregulated. These are not formal contraindications established by clinical trial data; they are mechanistic extrapolations from the preclinical literature. This site does not provide clinical guidance. ### Is TB-500 safe? Animal studies report favorable tolerability. Human safety data is limited to short-term Phase I trials of the full-length Tβ4 protein, which showed mostly mild, transient adverse events at IV doses up to 1260 mg in 40-person cohorts [9, 10]. TB-500 (the 7-residue synthetic fragment) has no published human safety trial. Long-term effects are unknown. The data supports 'apparently tolerated in controlled animal studies and in human Phase I trials of the full protein' — not 'proven safe.' ### Is TB-500 FDA approved? TB-500 is not FDA-approved for any human indication. It is studied as a research compound only. Full-length recombinant Tβ4 has been studied in Phase I and Phase 2 human trials with favorable tolerability in specific contexts [9, 10], but no FDA-approved product containing TB-500 or Tβ4 for systemic human use exists as of 2025. TB-500 is not a controlled substance under the Controlled Substances Act. --- A literature digest of peer-reviewed findings — not a clinic, not a prescription, not a vendor.